Alkermes reported favorable Phase 2 data for alixorexton, an orexin receptor agonist aimed at treating narcolepsy type 1, showing significant improvements in wakefulness and reductions in daytime sleepiness. Patients achieved normative wakefulness levels, and the drug was well tolerated with mild to moderate side effects. The results position Alkermes as a challenger to Takeda’s lead in the emerging class of narcolepsy drugs, with plans to advance alixorexton into Phase 3 trials. The trial also indicated potential improvements in cataplexy symptoms, though only one dose cohort reached statistical significance, prompting further methodological refinements.